Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. – Sarepta Therapeutics

CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jul. 21, 2025– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today, Sarepta Therapeutics notified the U.S. Food and Drug Adminis…

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com